The hottest Biotech Substack posts right now

And their main takeaways

Category

Top Business Topics

Biotech Week in Review | 03-03-2023

Engineering the Future • 0 implied HN points • 05 Mar 23

🔬 Science Biotech Health Technology

Viz.ai receives support for cardiomyopathy-spotting AI using ECG and ML for patient conditions
Big Pharma saw recovery in 2022 shifting focus from biotechs, providing stability and risk aversion
Chan Zuckerberg Initiative expanding to Chicago biohub emphasizing precision data for biotech advancements

Silicon Valley Bank in the spotlight

Boutique Biotech • 0 implied HN points • 11 Mar 23

💰 Finance Banking Biotech

Silicon Valley Bank's collapse is impacting many tech and biotech companies
The bank did business with about half of American tech and biotech companies
Cash-burning companies are now uncertain about the fate of their deposits

$XBI in the spotlight and trends to watch out for

Boutique Biotech • 0 implied HN points • 12 Apr 23

💰 Finance Biotech

Private money in biotech is accumulating but waiting to be deployed.
Q1 2023 saw the 4th strongest quarter for new capital raised by venture funds in 6 years.
Growing interest from investors to re-enter biopharma deals, particularly in private markets.

Biotech Update - 04.21.2023

Engineering the Future • 0 implied HN points • 21 Apr 23

🔬 Science Biotech Cancer Research Battery technology

Research shows contagious cancer in Tasmanian devils transmitted through biting
Noctrix Health introduces neurostimulation wearables for restless leg syndrome
Moderna collaborates with IBM for Quantum Computing and AI Training

Biotech Basics: Avoiding Common Pitfalls

Boutique Biotech • 0 implied HN points • 15 Jun 23

💰 Finance Biotech Investing

Biotech stock trading down after announcing 'successful results' could indicate data not being truly successful.
Companies may highlight cherry-picked positive results, while the overall study did not meet expectations.
It's important to be cautious when biotech companies start discussing specific parts of their studies.

Get a weekly roundup of the best Substack posts, by hacker news affinity:

Gossamer Bio in the spotlight

Boutique Biotech • 0 implied HN points • 21 Jun 23

💰 Finance Stocks Biotech Investing Pharmaceuticals

Gossamer Bio's stock fell in December 2022 after Phase 2 data release.
GOSS performed well in 'sicker' Class III PAH patients but not as well in 'less sick' Class II patients.
The post discusses a deep dive into the value and outlook of Gossamer Bio.

Biotech Basics: Medical Devices

Boutique Biotech • 0 implied HN points • 16 Jul 23

🏥 Health & Wellness Biotech Medical Devices

FDA approval process for medical devices is different from prescription drugs
Understanding FDA's medical device classification is important for stock market understanding
Discussion on hundreds of public companies commercializing their own medical devices

Gossamer Bio in the spotlight (part III)

Boutique Biotech • 0 implied HN points • 01 Aug 23

💰 Finance Biotech Investing

Gossamer Bio discussed Phase 2 results, OLE data, and Phase 3 design in a KOL call.
Some PAH patients reached a "normalized" level in the OLE continued seralutinib group.
The post is for paid subscribers only.

💥New Chapter 11 Bankruptcy - NanoString Technologies Inc. ($NSTG)💥

PETITION • 0 implied HN points • 11 Feb 24

💰 Finance Bankruptcy Biotech Legal

NanoString Technologies Inc. filed for Chapter 11 bankruptcy due to patent litigation, seeking a buyer.
NanoString is a biotech company supplying technologies for analyzing biological samples in pharmaceutical product development.
NanoString has a significant customer base including academic and government research facilities, biopharma companies, and clinical laboratories.

Y-Combinator’s 2024 RFS - Analyzing the Fastest Growing Companies Across Ep 2

Golden Pineapple • 0 implied HN points • 29 Feb 24

💼 Business Manufacturing Biotech

A top priority across various sectors is bringing manufacturing back to America, with bipartisan support and significant government investments.
SpaceX has shown the effectiveness of private space companies, with companies like Anduril proving the same in the defense technology sector.
Foundational models for biological systems and stablecoin finance are seeing significant growth, with companies like Science and Ava Labs leading the way.